RxDoctor Payments Data

Ram Puri, MD

Internal Medicine · Milledgeville, GANPI 1174518856

Payments from drug & device makers

$2,830in general payments, 2019–2025

Across 159 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$610
  • GSK$416
  • Novo Nordisk$259
  • Pfizer$171
  • Sanofi$163
  • Boehringer Ingelheim$121
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,830100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,830 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$184,914
Medicare patients
188
Services billed
6,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter294$284,998
EliquisApixaban224$202,333
RybelsusSemaglutide102$179,593
JardianceEmpagliflozin110$123,076
EntrestoSacubitril/Valsartan86$77,334
JanuviaSitagliptin Phosphate48$50,576
Spiriva RespimatTiotropium Bromide63$47,629
Repatha SureclickEvolocumab46$43,954
OzempicSemaglutide39$41,815
Breo ElliptaFluticasone/Vilanterol70$40,028
TradjentaLinagliptin48$36,497
XareltoRivaroxaban36$30,159
FarxigaDapagliflozin Propanediol27$26,170
SymbicortBudesonide/Formoterol Fumarate61$24,063
MyrbetriqMirabegron21$20,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$416$332,122377 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Stiolto Respimat, Combivent Respimat$121$242,137265 claims
Novo NordiskRybelsus, Ozempic$259$221,408141 claims
PfizerEliquis$171$202,333224 claims
NovartisEntresto$47$77,33486 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$610$69,814116 claims
MerckJanuvia$116$50,57648 claims
Johnson & JohnsonXarelto$12$30,15936 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$57$3,63512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Milledgeville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →